Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Accelerated treatment of infectious endocarditis
2023-507652-76-00Phase 4Authorised
- Sponsor
- Region Skåne
- Start
- Oct 2024
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of vancomycin, meropenem, ceftriaxone, benzylpenicillin, ampicillin and 3 more in endocarditis (IE) (2 arms), sponsored by Region Skåne. Primary endpoint: Composite clinical outcome at 6 months. Planned start Oct 2024; status: authorised.
02
Drugs
vancomycinmeropenemceftriaxonebenzylpenicillinampicillin
03
Conditions
endocarditis (IE)
Beyond the preview
Go deeper on 2023-507652-76-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507652-76-00.